secwatch / observer
8-K filed November 19, 2021, 6:59 PM ET ticker BOLT CIK 0001641281
leadership confidence high sentiment neutral materiality 0.40

Bolt Biotherapeutics appoints two new directors and lead independent director

Bolt Biotherapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Moldt

Director
BOLT · Bolt Biotherapeutics, Inc.
Effective
2021-11-15
Filed
November 19, 2021, 6:59 PM ET
On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
Appointed

Frank Lee

Director
BOLT · Bolt Biotherapeutics, Inc.
Effective
2021-11-17
Filed
November 19, 2021, 6:59 PM ET
The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately
Role change

Jim Healy

Lead Independent Director
BOLT · Bolt Biotherapeutics, Inc.
Effective
2021-11-17
Filed
November 19, 2021, 6:59 PM ET
the Board appointed Jim Healy, an existing member of the Board, to serve as the lead independent director of the Company
Appointed

Brian O'Callaghan

Director
BOLT · Bolt Biotherapeutics, Inc.
Effective
2021-11-17
Filed
November 19, 2021, 6:59 PM ET
The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Moldt resigned as Director at Bolt Biotherapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Frank Lee was appointed as Director at Bolt Biotherapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Healy was appointed as Lead Independent Director at Bolt Biotherapeutics, Inc..

Action
appointed
Role
Lead Independent Director
Exact text from the filing
the Board appointed Jim Healy, an existing member of the Board, to serve as the lead independent director of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brian O'Callaghan was appointed as Director at Bolt Biotherapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately
View on SEC.gov

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001564590-21-057696
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.